市場調査レポート

商品コード

1540964

抗リウマチ薬市場レポート：タイプ別、薬剤クラス別、薬剤投与経路別、流通チャネル別、地域別、2024年～2032年

Anti-Rheumatics Market Report by Type, Drug Class, Route of Drug Administration, Distribution Channel, and Region 2024-2032

出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 140 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 443,522円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcelの印刷は一度のみ可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (5 User License)

USD 3,999 591,412円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcelの印刷は可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 739,302円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等の編集は可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=147.89円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の抗リウマチ薬市場規模は2023年に645億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて2.4%の成長率（CAGR）を示し、2032年には804億米ドルに達すると予測しています。世界の高齢化の進展、病院や診療所などのヘルスケア施設の拡大、大手製薬会社とヘルスケアセンターとのパートナーシップの拡大などが、市場成長を後押しする主な要因となっています。

抗リウマチ薬は、関節、筋肉、結合組織に影響を及ぼす疾患の治療に用いられる医薬品です。炎症、痛み、こわばりを抑え、病気の進行を遅らせる効果があります。非ステロイド性抗炎症薬（NSAIDs）、疾患修飾性抗リウマチ薬（DMARDs）、生物学的製剤など様々なクラスがあります。これらの薬剤は経口、皮下、静脈から体内に投与することができます。これらの薬剤は、組織の損傷や炎症を引き起こす根本的なメカニズムを標的とします。一般的に、これらの薬剤は十分な診断の後に処方され、最適な結果を得るために併用されます。

不健康な食事パターンや運動不足に起因するリウマチ性疾患の有病率の上昇は、効果的な治療に対する需要を喚起する重要な要因の一つです。さらに、ナノ粒子ベースのキャリアや時間放出カプセルのようなドラッグデリバリーシステムの継続的な開発により、抗リウマチ薬の有効性と利便性が向上しています。これとは別に、遠隔医療サービスの成長により、より良い疾病管理と簡単な処方補充が可能になり、抗リウマチ薬の一貫した使用が促進されています。さらに、新興市場へのヘルスケアシステムの拡大により、十分なサービスを受けていない人々にとっても抗リウマチ薬が利用しやすくなっています。さらに、ゲノミクスと個別化医療の進歩により、より的を絞った治療が可能になり、抗リウマチ薬の有効性が向上しています。

抗リウマチ薬市場傾向/促進要因：

高齢化人口の増加

変形性関節症や関節リウマチなどの関節疾患に罹患しやすい高齢化人口の増加は、市場の成長を増大させる重要な要因の1つです。さらに、高齢者はリウマチ性疾患を悪化させる複数の健康状態にあることが多く、より複雑で長期的な治療戦略が必要となります。さらに、各国の行政当局やヘルスケアシステムはこのニーズの高まりを認識しており、高齢化社会の課題に対処するためにヘルスケア予算を増額しています。製薬企業もまた、より効果的で安全な抗リウマチ薬の創製に研究開発に力を注いでいます。その結果、抗リウマチ薬市場は今後数年間で大きく成長すると予想されます。

戦略的提携と合併

製薬企業やヘルスケア施設間の戦略的提携、合併、買収（M&A）が増加していることも、市場成長の主な要因です。M&Aには知識共有契約が含まれることが多く、規制上のハードルを乗り越えるのが容易になり、新薬の市場投入までの時間が短縮されます。さらに、大手製薬企業とバイオベンチャー企業との提携が拡大することで、抗リウマチ薬の新薬開発と商業化がより迅速に行われるようになります。これとは別に、より先進的な医薬品を導入するための研究開発（R&D）活動も促進されます。さらに、このような協力関係は、これまで未開拓であった市場への抗リウマチ薬の容易な供給を促進し、世界市場の成長に寄与しています。

早期診断と予防に対する意識の高まり

リウマチ性疾患の早期診断と予防の利点に関する個人の意識の高まりが、市場の成長を強化しています。早期診断により、抗リウマチ薬の使用が必要となることが多い疾患を、より効果的に管理することができます。さらに、医療教育を促進するソーシャルメディア・チャンネルへの依存度が高まっていることも、市場にプラスの影響を与えています。さらに、数カ国の行政当局が公衆衛生キャンペーンを実施しており、市場の見通しを良好なものにしています。さらに、高度な診断ツールの開発により、医療従事者はリウマチ性疾患を早期に発見しやすくなっています。このような積極的なアプローチは、抗リウマチ薬の市場需要を高めます。タイムリーな介入には、症状管理や疾患改善のための投薬が必要だからです。

北米
- 米国
- カナダ
アジア太平洋
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
中東・アフリカ
- 市場動向
- 市場内訳：国別
- 市場予測

第11章 SWOT分析

概要
強み
弱み
機会
脅威

第12章バリューチェーン分析

第13章ポーターのファイブフォース分析

概要
買い手の交渉力
供給企業の交渉力
競合の程度
新規参入業者の脅威
代替品の脅威

第14章価格分析

第15章競合情勢

市場構造
主要企業
主要企業のプロファイル
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca plc
- Biogen Inc.
- Bristol-Myers Squibb Company
- Celltrion Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Johnson & Johnsons
- Pfizer Inc.
- Sanofi SA

図表

List of Figures

Figure 1: Global: Anti-Rheumatics Market: Major Drivers and Challenges
Figure 2: Global: Anti-Rheumatics Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Anti-Rheumatics Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Anti-Rheumatics Market: Breakup by Type (in %), 2023
Figure 5: Global: Anti-Rheumatics Market: Breakup by Drug Class (in %), 2023
Figure 6: Global: Anti-Rheumatics Market: Breakup by Route of Drug Administration (in %), 2023
Figure 7: Global: Anti-Rheumatics Market: Breakup by Distribution Channel (in %), 2023
Figure 8: Global: Anti-Rheumatics Market: Breakup by Region (in %), 2023
Figure 9: Global: Anti-Rheumatics (Prescription-based Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 10: Global: Anti-Rheumatics (Prescription-based Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 11: Global: Anti-Rheumatics (Over-the-Counter Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 12: Global: Anti-Rheumatics (Over-the-Counter Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 13: Global: Anti-Rheumatics (Disease Modifying Anti-Rheumatics Drugs (DMARD's)) Market: Sales Value (in Million US$), 2018 & 2023
Figure 14: Global: Anti-Rheumatics (Disease Modifying Anti-Rheumatics Drugs (DMARD's)) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 15: Global: Anti-Rheumatics (Nonsteroidal Anti-Inflammatory Drugs (NSAID's)) Market: Sales Value (in Million US$), 2018 & 2023
Figure 16: Global: Anti-Rheumatics (Nonsteroidal Anti-Inflammatory Drugs (NSAID's)) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 17: Global: Anti-Rheumatics (Corticosteroids) Market: Sales Value (in Million US$), 2018 & 2023
Figure 18: Global: Anti-Rheumatics (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 19: Global: Anti-Rheumatics (Uric Acid Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 20: Global: Anti-Rheumatics (Uric Acid Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 21: Global: Anti-Rheumatics (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
Figure 22: Global: Anti-Rheumatics (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 23: Global: Anti-Rheumatics (Oral) Market: Sales Value (in Million US$), 2018 & 2023
Figure 24: Global: Anti-Rheumatics (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 25: Global: Anti-Rheumatics (Parenteral) Market: Sales Value (in Million US$), 2018 & 2023
Figure 26: Global: Anti-Rheumatics (Parenteral) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 27: Global: Anti-Rheumatics (Other Routes of Drug Administration) Market: Sales Value (in Million US$), 2018 & 2023
Figure 28: Global: Anti-Rheumatics (Other Routes of Drug Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 29: Global: Anti-Rheumatics (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 30: Global: Anti-Rheumatics (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 31: Global: Anti-Rheumatics (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 32: Global: Anti-Rheumatics (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 33: Global: Anti-Rheumatics (E-Commerce) Market: Sales Value (in Million US$), 2018 & 2023
Figure 34: Global: Anti-Rheumatics (E-Commerce) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 35: North America: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 36: North America: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 37: United States: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 38: United States: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 39: Canada: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 40: Canada: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 41: Asia-Pacific: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 42: Asia-Pacific: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 43: China: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 44: China: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 45: Japan: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 46: Japan: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 47: India: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 48: India: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 49: South Korea: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 50: South Korea: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 51: Australia: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 52: Australia: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 53: Indonesia: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 54: Indonesia: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 55: Others: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 56: Others: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 57: Europe: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 58: Europe: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 59: Germany: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 60: Germany: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 61: France: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 62: France: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 63: United Kingdom: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 64: United Kingdom: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 65: Italy: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 66: Italy: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 67: Spain: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 68: Spain: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 69: Russia: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 70: Russia: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 71: Others: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 72: Others: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 73: Latin America: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 74: Latin America: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 75: Brazil: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 76: Brazil: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 77: Mexico: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 78: Mexico: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 79: Others: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 80: Others: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 81: Middle East and Africa: Anti-Rheumatics Market: Sales Value (in Million US$), 2018 & 2023
Figure 82: Middle East and Africa: Anti-Rheumatics Market: Breakup by Country (in %), 2023
Figure 83: Middle East and Africa: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 84: Global: Anti-Rheumatics Industry: SWOT Analysis
Figure 85: Global: Anti-Rheumatics Industry: Value Chain Analysis
Figure 86: Global: Anti-Rheumatics Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Anti-Rheumatics Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Anti-Rheumatics Market Forecast: Breakup by Type (in Million US$), 2024-2032
Table 3: Global: Anti-Rheumatics Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
Table 4: Global: Anti-Rheumatics Market Forecast: Breakup by Route of Drug Administration (in Million US$), 2024-2032
Table 5: Global: Anti-Rheumatics Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 6: Global: Anti-Rheumatics Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 7: Global: Anti-Rheumatics Market: Competitive Structure
Table 8: Global: Anti-Rheumatics Market: Key Players

Product Code: SR112024A4148

The global anti-rheumatics market size reached US$ 64.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 80.4 Billion by 2032, exhibiting a growth rate (CAGR) of 2.4% during 2024-2032. The increasing aging population across the globe, expansion of hospitals, clinics, and other healthcare facilities, and the expanding partnerships between large pharmaceutical companies and healthcare centers are some of the major factors propelling the market growth.

Anti-rheumatics are medications used to treat diseases affecting the joints, muscles, and connective tissues. They help reduce inflammation, pain, and stiffness, and slow the progression of the disease. They are available in various classes, including non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), and biologics. They can be administered orally, subcutaneously and intravenously into the body. They target the underlying mechanisms that lead to tissue damage and inflammation. They are generally prescribed after a thorough diagnosis and are used in combination for optimum results.

The rising prevalence of rheumatic diseases due to unhealthy dietary patterns and lack of physical activity represent one of the key factors catalyzing the demand for effective treatments. Additionally, continuous development in drug delivery systems, like nanoparticle-based carriers or time-release capsules, is enhancing the efficacy and convenience of anti-rheumatic medications. Apart from this, the growth of telehealth services is enabling better disease management and easier prescription refills, promoting consistent use of anti-rheumatic drugs. Furthermore, the expansion of healthcare systems into emerging markets is making anti-rheumatic medications more accessible to underserved populations. Moreover, advancements in genomics and personalized medicine are allowing for more targeted treatments and improving the effectiveness of anti-rheumatic medications.

Anti-Rheumatics Market Trends/Drivers:

Rising aging population

The increasing aging population, which is more susceptible to joint disorders, such as osteoarthritis and rheumatoid arthritis, represents one of the key factors augmenting the market growth. Moreover, older populations often have multiple health conditions that can exacerbate rheumatic diseases, thus requiring more complex and long-term treatment strategies. Additionally, governing authorities and healthcare systems of various countries are recognizing this growing need and are increasing healthcare budgets to address the challenges of an aging society. Pharmaceutical companies are also focusing their research and development efforts on creating more effective and safer anti-rheumatic medications. As a result, the market for these drugs is expected to grow substantially in the coming years.

Strategic collaborations and mergers

The increasing number of strategic collaborations, mergers, and acquisitions (M&A) among pharmaceutical companies and healthcare facilities is another major factor contributing to the market growth. They often include knowledge-sharing agreements, making it easier to navigate regulatory hurdles and reducing the time-to-market for new medications. Additionally, the expanding partnerships between large pharmaceutical companies and biotech startups result in the faster development and commercialization of new anti-rheumatic drugs. Apart from this, it facilitates research and development (R&D) activities to introduce more advanced drugs. Furthermore, these collaborations promote an easy supply of anti-rheumatic drugs to reach previously untapped markets, contributing to global market growth.

Rising awareness about early diagnosis and prevention

The rising awareness among individuals about the benefits of early diagnosis and prevention of rheumatoid diseases is strengthening the growth of the market. Early diagnosis allows for more effective management of the disease, often requiring the use of anti-rheumatic drugs. Additionally, the increasing reliance of people on social media channels promoting medical education is positively influencing the market. Furthermore, the governing authorities of several countries are organizing public health campaigns, which is offering a favorable market outlook. Moreover, the development of advanced diagnostic tools has made it easier for healthcare professionals to identify rheumatic diseases at an early stage. This proactive approach enhances the market demand for anti-rheumatics, as timely intervention necessitates medication for symptom management and disease modification.

Anti-Rheumatics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global anti-rheumatics market report, along with forecasts at the global regional, and country levels from 2024-2032. Our report has categorized the market based on type, drug class, route of drug administration and, distribution channel.

Breakup by Type:

Prescription-based Drugs

Over-the-Counter Drugs

Prescription-based drugs account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the type. This includes prescription-based drugs and over-the-counter drugs. According to the report, prescription-based drugs represented the largest segment as they are usually more potent and targeted compared to over the counter (OTC) options. Additionally, prescription- based medications are generally more likely to be covered by insurance plans, making them financially accessible for a larger patient population. The ease of insurance claims for prescription drugs further promotes their usage and contributes to their larger market share. Apart from this, they come with the advantage of regular healthcare provider reviews, allowing for ongoing adjustments to the treatment regimen based on the course of the diseases and patient response. Furthermore, the latest innovations in anti-rheumatic treatments are often patented prescription medications. Pharmaceutical companies invest significantly in R&D to develop novel prescription drugs, ensuring that the most advanced treatment options are primarily available in prescription form.

Breakup by Drug Class:

Disease Modifying Anti-Rheumatics Drugs (DMARD's)

Nonsteroidal Anti-Inflammatory Drugs (NSAID's)

Corticosteroids

Uric Acid Drugs

Others

Disease modifying anti-rheumatics drugs (DMARD's) hold the largest share in the industry

A detailed breakup and analysis of the market based on the drug class has also been provided in the report. This includes disease modifying anti-rheumatics drugs (DMARD's), nonsteroidal anti-inflammatory drugs (NSAID's), corticosteroids, uric acid drugs, and others. According to the report, disease modifying anti-rheumatics drugs (DMARD's) accounted for the largest market share as they work at a cellular level to modulate the immune response and aid in effectively altering the course of rheumatic diseases. Additionally, they help reduce the frequency of hospital visits, surgeries, and other expensive medical interventions. Apart from this, in many healthcare systems, DMARDs are included in insurance coverage plans, making them financially accessible to a larger population. Effective reimbursement policies further encourage the prescription of DMARDs, thus enhancing their market share. Moreover, continuous advancements in personalized medicine are leading to the development of more targeted DMARD therapies, enhancing their efficacy and reducing potential side effects, thereby reinforcing their market dominance.

Breakup by Route of Drug Administration:

Oral

Parenteral

Others

Parenteral represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the route of drug administration. This includes oral, parenteral, and others. According to the report, parenteral represented the largest segment as it allows for the direct delivery of drug into the bloodstream or target tissue, bypassing the gastrointestinal system. This results in a quicker onset of action and often increased efficacy compared to oral medications, which is a crucial factor in treating acute flare-ups or severe cases of rheumatic diseases. Apart from this, physicians often prefer parenteral administration for its rapid action, especially in hospital settings where immediate symptom relief or disease control is required. Moreover, parenteral medications undergo stringent quality control measures to ensure sterility and potency, which adds another layer of assurance for both healthcare providers and patients. Furthermore, many parenteral formulations are available in pre-filled syringes or auto-injectors, making it easier for patients to self-administer their medication, thereby enhancing adherence to treatment plans.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

E-Commerce

Hospital pharmacies exhibit a clear dominance in the market

A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and e-commerce. According to the report, hospital pharmacies hold the majority of the market share as they are generally situated in close proximity to consultation rooms, diagnostic services, and treatment areas. This centralization allows for the immediate dispensing of anti-rheumatic medications following a diagnosis or prescription revision, providing an advantage in terms of convenience and speed over retail or online pharmacies. Additionally, pharmacists in hospital settings often have specialized training and experience in managing chronic diseases, including rheumatic conditions. They work in close collaboration with healthcare teams, including rheumatologists and nurses, ensuring that patients receive the most appropriate medication for their condition. Apart from this, they operate round-the-clock, ensuring that medications are available during emergencies or off-hours.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest anti-rheumatics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share since the region is a hub for pharmaceutical research and development (R&D). Additionally, North America, particularly the United States, has a well-established healthcare system equipped with state-of-the-art medical facilities. This superior infrastructure allows for the early diagnosis and comprehensive treatment of rheumatic diseases, which naturally leads to a higher demand for anti-rheumatic medications. Along with this, the widespread availability of specialized rheumatology clinics and medical professionals further drives the need for these drugs. Apart from this, the regulatory environment in North America, led by agencies like the U.S. Food and Drug Administration (FDA), is highly supportive of medical advancements. Furthermore, the increasing aging population in the region is driving the demand for anti-rheumatics.

Competitive Landscape:

Companies are investing heavily in the development of new anti-rheumatic drugs, targeting existing and emerging therapeutic mechanisms. Additionally, many companies are entering into partnerships, mergers, and acquisitions. These strategic collaborations often involve sharing technology, resources, and market channels. Apart from this, they are also focusing on expanding market access through various channels. This often involves launching products in new geographical markets, increasing production capacities, or diversifying supply chains to ensure more reliable distribution. Furthermore, various companies are using analytics to identify market trends, patient preferences, and treatment outcomes. Moreover, they are investing in educational programs for healthcare providers, patients, and the public.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AbbVie Inc.

Amgen Inc.

AstraZeneca plc

Biogen Inc.

Bristol-Myers Squibb Company

Celltrion Inc.

Eli Lilly and Company

F. Hoffmann-La Roche AG

Johnson & Johnsons

Pfizer Inc.

Sanofi SA

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Recent Developments:

In July 2023, AbbVie Inc. announced that the first patient has been dosed in the Phase 3 Step-Up HS study to evaluate upadacitinib (RINVOQ(R)) in adults and adolescents with moderate to severe hidradenitis suppurativa (HS) symptoms and have failed anti-tumor necrosis factor (TNF) therapy and one approved non-anti-TNF inhibitor therapy for HS.1

In November 2022, Amgen Inc. announced that clinical and real-world data across its broad portfolio of established treatments and pipeline assets will be presented at the annual American College of Rheumatology Convergence (ACR).

In September 2022, Biogen Inc. announced that the European Medicines Agency (EMA) had accepted the Marketing Authorization Application (MAA) for BIIB800, a biosimilar candidate referencing RoACTEMRA(R)1 (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody.

Key Questions Answered in This Report

1. What was the size of the global anti-rheumatics market in 2023?
2. What is the expected growth rate of the global anti-rheumatics market during 2024-2032?
3. What are the key factors driving the global anti-rheumatics market?
4. What has been the impact of COVID-19 on the global anti-rheumatics market?
5. What is the breakup of the global anti-rheumatics market based on the type?
6. What is the breakup of the global anti-rheumatics market based on the drug class?
7. What is the breakup of the global anti-rheumatics market based on the route of drug administration?
8. What is the breakup of the global anti-rheumatics market based on the distribution channel?
9. What are the key regions in the global anti-rheumatics market?
10. Who are the key players/companies in the global anti-rheumatics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Anti-Rheumatics Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Type

6.1 Prescription-based Drugs
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Over-the-Counter Drugs
- 6.2.1 Market Trends
- 6.2.2 Market Forecast

7 Market Breakup by Drug Class

7.1 Disease Modifying Anti-Rheumatics Drugs (DMARD's)
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Nonsteroidal Anti-Inflammatory Drugs (NSAID's)
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Corticosteroids
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Uric Acid Drugs
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast

8 Market Breakup by Route of Drug Administration

8.1 Oral
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Parenteral
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 E-Commerce
- 9.3.1 Market Trends
- 9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia-Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 AbbVie Inc.
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
  - 15.3.1.4 SWOT Analysis
- 15.3.2 Amgen Inc.
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 Financials
  - 15.3.2.4 SWOT Analysis
- 15.3.3 AstraZeneca plc
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
  - 15.3.3.4 SWOT Analysis
- 15.3.4 Biogen Inc.
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
  - 15.3.4.4 SWOT Analysis
- 15.3.5 Bristol-Myers Squibb Company
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
  - 15.3.5.4 SWOT Analysis
- 15.3.6 Celltrion Inc.
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
  - 15.3.6.4 SWOT Analysis
- 15.3.7 Eli Lilly and Company
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
  - 15.3.7.4 SWOT Analysis
- 15.3.8 F. Hoffmann-La Roche AG
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
- 15.3.9 Johnson & Johnsons
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 Pfizer Inc.
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
  - 15.3.10.3 Financials
  - 15.3.10.4 SWOT Analysis
- 15.3.11 Sanofi SA
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio
  - 15.3.11.3 Financials
  - 15.3.11.4 SWOT Analysis

抗リウマチ薬市場レポート：タイプ別、薬剤クラス別、薬剤投与経路別、流通チャネル別、地域別、2024年～2032年

Anti-Rheumatics Market Report by Type, Drug Class, Route of Drug Administration, Distribution Channel, and Region 2024-2032

抗リウマチ薬市場傾向/促進要因：

目次

第1章 序文

第2章 調査範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の抗リウマチ薬市場

第6章 市場内訳：タイプ別

第7章 市場内訳：薬剤クラス別

第8章 市場内訳：薬剤投与経路別

第9章 市場内訳：流通チャネル別

第10章 市場内訳：地域別

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢

List of Figures

List of Tables

Anti-Rheumatics Market Trends/Drivers:

Anti-Rheumatics Industry Segmentation:

Breakup by Type:

Breakup by Drug Class:

Breakup by Route of Drug Administration:

Breakup by Distribution Channel:

Breakup by Region:

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Recent Developments:

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Anti-Rheumatics Market

6 Market Breakup by Type

7 Market Breakup by Drug Class

8 Market Breakup by Route of Drug Administration

9 Market Breakup by Distribution Channel

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape

第1章序文

第2章調査範囲と調査手法

第3章エグゼクティブサマリー

第4章イントロダクション

第5章世界の抗リウマチ薬市場

第6章市場内訳：タイプ別

第7章市場内訳：薬剤クラス別

第8章市場内訳：薬剤投与経路別

第9章市場内訳：流通チャネル別

第10章市場内訳：地域別

第12章バリューチェーン分析

第13章ポーターのファイブフォース分析

第14章価格分析

第15章競合情勢